

Ref: EPL/CS/SE/0046/2026

Date: May 16, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration ("US FDA") conducted a current Good Manufacturing Practices (cGMP) inspection at the Company's formulations facility located at G.I.D.C., Taluka - Sanand, Ahmedabad - 382110, Gujarat, from May 06, 2026 to May 15, 2026. At the conclusion of the inspection, the Company was issued a Form 483 with 7 observation(s). The observations are procedural in nature.

We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Amruta Yangelwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251